Viking Therapeutics Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
Viking Therapeutics's earnings have been declining at an average annual rate of -25.6%, while the Biotechs industry saw earnings growing at 19% annually.
Anahtar bilgiler
-25.6%
Kazanç büyüme oranı
-18.3%
EPS büyüme oranı
Biotechs Sektör Büyümesi | 17.0% |
Gelir büyüme oranı | n/a |
Özkaynak getirisi | -10.9% |
Net Marj | n/a |
Son Kazanç Güncellemesi | 30 Sep 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
Viking Therapeutics: Too Much Excitement Around Oral VK2735, Even If It Met High Expectations
Nov 04Viking Therapeutics: Lots Of Positives
Oct 28Viking Therapeutics: Market Rightly Excited By GLP-1 Promise -- A Buy Ahead Of Data
Sep 25Companies Like Viking Therapeutics (NASDAQ:VKTX) Can Afford To Invest In Growth
Sep 07Viking Therapeutics: GLP-1/GIP Receptor Agonist And Its Competitive Landscape
Aug 30Viking Therapeutics: Better-Than-Expected Trial Timelines While Pipeline Expands
Jul 25We Think Viking Therapeutics (NASDAQ:VKTX) Can Easily Afford To Drive Business Growth
Apr 26Viking Therapeutics: Future Weight Loss Heavyweight?
Apr 02We're Hopeful That Viking Therapeutics (NASDAQ:VKTX) Will Use Its Cash Wisely
Jan 09We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate
Sep 21Viking Therapeutics (NASDAQ:VKTX) Is In A Good Position To Deliver On Growth Plans
Jun 07We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate
Mar 05Viking Therapeutics: Playing Second Fiddle To Madrigal
Aug 30We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth
Jul 13Revisiting Viking Therapeutics
Apr 20We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth
Apr 12We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth
Dec 17Viking Therapeutics: Remaining Bullish And Sticking To My Plan
Aug 27Viking Therapeutics soars 11% on encouraging VK0214 data in rare metabolic disorder
Jun 17Have Insiders Been Selling Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares This Year?
Jan 13Viking Therapeutics announces senior management appointments
Jan 06Do Institutions Own Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares?
Dec 09Viking Therapeutics: Progressing Steadily, But Concerns Remain
Nov 29Gelir ve Gider Dağılımı
Viking Therapeutics nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
---|---|---|---|---|
30 Sep 24 | 0 | -99 | 43 | 91 |
30 Jun 24 | 0 | -97 | 38 | 87 |
31 Mar 24 | 0 | -94 | 37 | 77 |
31 Dec 23 | 0 | -86 | 37 | 64 |
30 Sep 23 | 0 | -81 | 32 | 59 |
30 Jun 23 | 0 | -74 | 28 | 53 |
31 Mar 23 | 0 | -72 | 22 | 53 |
31 Dec 22 | 0 | -69 | 16 | 54 |
30 Sep 22 | 0 | -62 | 15 | 48 |
30 Jun 22 | 0 | -59 | 13 | 47 |
31 Mar 22 | 0 | -57 | 12 | 46 |
31 Dec 21 | 0 | -55 | 11 | 45 |
30 Sep 21 | 0 | -54 | 10 | 44 |
30 Jun 21 | 0 | -50 | 10 | 41 |
31 Mar 21 | 0 | -44 | 10 | 35 |
31 Dec 20 | 0 | -39 | 11 | 32 |
30 Sep 20 | 0 | -36 | 11 | 29 |
30 Jun 20 | 0 | -32 | 10 | 27 |
31 Mar 20 | 0 | -31 | 10 | 27 |
31 Dec 19 | 0 | -26 | 9 | 24 |
30 Sep 19 | 0 | -24 | 9 | 22 |
30 Jun 19 | 0 | -24 | 8 | 23 |
31 Mar 19 | 0 | -23 | 8 | 20 |
31 Dec 18 | 0 | -22 | 7 | 19 |
30 Sep 18 | 0 | -21 | 7 | 17 |
30 Jun 18 | 0 | -20 | 6 | 15 |
31 Mar 18 | 0 | -19 | 6 | 13 |
31 Dec 17 | 0 | -21 | 5 | 14 |
30 Sep 17 | 0 | -20 | 5 | 13 |
30 Jun 17 | 0 | -18 | 5 | 12 |
31 Mar 17 | 0 | -16 | 5 | 11 |
31 Dec 16 | 0 | -15 | 5 | 9 |
30 Sep 16 | 0 | -16 | 5 | 10 |
30 Jun 16 | 0 | -17 | 6 | 10 |
31 Mar 16 | 0 | -21 | 6 | 9 |
31 Dec 15 | 0 | -23 | 5 | 7 |
30 Sep 15 | 0 | -17 | 4 | 4 |
30 Jun 15 | 0 | -12 | 2 | 2 |
31 Mar 15 | 0 | -27 | 1 | 22 |
31 Dec 14 | 0 | -22 | 1 | 22 |
30 Sep 14 | 0 | -23 | 1 | 22 |
30 Jun 14 | 0 | -23 | 1 | 21 |
31 Mar 14 | 0 | 0 | 0 | 0 |
Kaliteli Kazançlar: VKTX is currently unprofitable.
Büyüyen Kar Marjı: VKTX is currently unprofitable.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: VKTX is unprofitable, and losses have increased over the past 5 years at a rate of 25.6% per year.
Büyüme Hızlandırma: Unable to compare VKTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Kazançlar vs. Sektör: VKTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Özkaynak Getirisi
Yüksek ROE: VKTX has a negative Return on Equity (-10.88%), as it is currently unprofitable.